Literature DB >> 23640191

Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations.

Linda Björkhem-Bergman1, Eva Andersén-Karlsson, Richard Laing, Eduardo Diogene, Oyvind Melien, Malena Jirlow, Rickard E Malmström, Sabine Vogler, Brian Godman, Lars L Gustafsson.   

Abstract

PURPOSE: In September 2012 an interactive course on the "Interface Management of Pharmacotherapy" was organized by the Stockholm Drug and Therapeutics Committee in cooperation with Department of Clinical Pharmacology at Karolinska Institutet and at Karolinska University Hospital in Stockholm, Sweden, in collaboration with the WHO. The basis for the course was the "Stockholm model" for the rational use of medicines but also contained presentations about successful models in interface management of pharmacotherapy in other European countries.
METHODS: The "Stockholm model" consists of 8 components: 1) Independent Drug and Therapeutics Committee with key role for respected drug experts with policy for "interest of conflicts", 2) The "Wise List", recommendations of medicines jointly for primary and hospital care, 3) Communication strategy with continuous medical education, 4) Systematic introduction of new expensive medicines, 5) E-pharmacological support at "point of care", 6) Methods and tools for follow-up of medicines use, 7) Medicines policy strategy and 8) Operative resources.
RESULTS: The course highlighted the importance of efficient and targeted communication of drug recommendations building on trust among prescribers and patients for the guidelines to achieve high adherence. Trust is achieved by independent Drug and Therapeutics Committees with a key role for respected experts and a strict policy for "conflicts of interest". Representations of GPs are also crucial for successful implementation, being the link between evidence based medicine and practice.
CONCLUSION: The successful models in Scotland and in Stockholm as well as the ongoing work in Catalonia were considered as examples of multifaceted approaches to improve the quality of medicine use across primary and hospital care.

Entities:  

Mesh:

Year:  2013        PMID: 23640191     DOI: 10.1007/s00228-013-1497-5

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

Review 1.  25 years of the WHO essential medicines lists: progress and challenges.

Authors:  Richard Laing; Brenda Waning; Andy Gray; Nathan Ford; Ellen 't Hoen
Journal:  Lancet       Date:  2003-05-17       Impact factor: 79.321

2.  Essential drugs programmes in Africa.

Authors:  R Laing
Journal:  Afr Health       Date:  1991-11

3.  Management of medication use in Scotland.

Authors:  Jordan R Covvey; Stuart McTaggart; Iain Bishop
Journal:  Am J Health Syst Pharm       Date:  2010-08-15       Impact factor: 2.637

4.  What public policies have been more effective in promoting rational prescription of drugs?

Authors:  Eduard Diogène; Albert Figueras
Journal:  J Epidemiol Community Health       Date:  2010-12-16       Impact factor: 3.710

5.  Design and implementation of a point-of-care computerized system for drug therapy in Stockholm metropolitan health region--Bridging the gap between knowledge and practice.

Authors:  Bengt Sjöborg; Tobias Bäckström; Lars-Bertil Arvidsson; Eva Andersén-Karlsson; L Bengt Blomberg; Birgit Eiermann; Marie Eliasson; Kjell Henriksson; Lennart Jacobsson; Ulf Jacobsson; Margaretha Julander; Per-Olof Kaiser; Carina Landberg; Jonas Larsson; Björn Molin; Lars L Gustafsson
Journal:  Int J Med Inform       Date:  2006-04-19       Impact factor: 4.046

6.  Scottish Medicines Consortium: an overview of rapid new drug assessment in Scotland.

Authors:  J Dear; C O'Dowd; A Timoney; K R Paterson; A Walker; D J Webb
Journal:  Scott Med J       Date:  2007-08       Impact factor: 0.729

7.  SFINX-a drug-drug interaction database designed for clinical decision support systems.

Authors:  Ylva Böttiger; Kari Laine; Marine L Andersson; Tuomas Korhonen; Björn Molin; Marie-Louise Ovesjö; Tuire Tirkkonen; Anders Rane; Lars L Gustafsson; Birgit Eiermann
Journal:  Eur J Clin Pharmacol       Date:  2009-02-11       Impact factor: 2.953

8.  A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing.

Authors:  Brian Godman; Lars L Gustafsson
Journal:  Appl Health Econ Health Policy       Date:  2013-02       Impact factor: 2.561

9.  Medication errors when transferring elderly patients between primary health care and hospital care.

Authors:  Patrik Midlöv; Anna Bergkvist; Asa Bondesson; Tommy Eriksson; Peter Höglund
Journal:  Pharm World Sci       Date:  2005-04

10.  A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing.

Authors:  Ulf Persson; Johanna Svensson; Billie Pettersson
Journal:  Appl Health Econ Health Policy       Date:  2012-07-01       Impact factor: 2.561

View more
  23 in total

1.  Do educational meetings and group detailing change adherence to drug formularies in hospitals? A cluster randomized controlled trial.

Authors:  Hanne T Plet; Lene J Kjeldsen; René de Pont Christensen; Gitte S Nielsen; Jesper Hallas
Journal:  Eur J Clin Pharmacol       Date:  2014-01       Impact factor: 2.953

2.  Compliance with quality prescribing indicators linked to financial incentives: what about not incentivized indicators?: an observational study.

Authors:  R Fernández Urrusuno; P Pérez Pérez; M C Montero Balosa; C Márquez Calzada; B Pascual de la Pisa
Journal:  Eur J Clin Pharmacol       Date:  2013-12-03       Impact factor: 2.953

3.  Providing a framework for assessment of the access to medicine.

Authors:  Monireh Afzali; Elahe Khorasani; Mahdi Alvandi; Mansoureh Sabbagh-Bani-Azad; Zahra Sharif; Parisa Saiyarsarai; Shekoufeh Nikfar
Journal:  Daru       Date:  2019-05-04       Impact factor: 3.117

4.  Perceptions, Expectations, and Experience of Physicians About Pharmacists and Pharmaceutical Care Services in Pakistan: Findings and Implications.

Authors:  Khezar Hayat; Zia Ul Mustafa; Brain Godman; Muhammad Arshed; Jiaxing Zhang; Faiz Ullah Khan; Fahad Saleem; Krizzia Lambojon; Pengchao Li; Zhitong Feng; Yu Fang
Journal:  Front Pharmacol       Date:  2021-05-14       Impact factor: 5.810

5.  Prescribing efficiency of proton pump inhibitors in China: influence and future directions.

Authors:  Wenjie Zeng; Alexander E Finlayson; Sushma Shankar; Winnie de Bruyn; Brian Godman
Journal:  BMC Health Serv Res       Date:  2015-01-22       Impact factor: 2.655

Review 6.  Factors affecting the uptake of new medicines: a systematic literature review.

Authors:  Ágnes Lublóy
Journal:  BMC Health Serv Res       Date:  2014-10-20       Impact factor: 2.655

7.  High adherence to the 'Wise List' treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines.

Authors:  Jaran Eriksen; Lars L Gustafsson; Kristina Ateva; Pia Bastholm-Rahmner; Marie-Louise Ovesjö; Malena Jirlow; Maria Juhasz-Haverinen; Gerd Lärfars; Rickard E Malmström; Björn Wettermark; Eva Andersén-Karlsson
Journal:  BMJ Open       Date:  2017-05-02       Impact factor: 2.692

8.  Patients' knowledge and attitudes to the Wise List - a drug formulary from the Stockholm Drug and Therapeutic committee.

Authors:  Pia Bastholm-Rahmner; Lars L Gustafsson; Kristina Aggefors; Kristina Ateva; Susanne Elfving; Jaran Eriksen; Malena Jirlow; Maria Juhasz-Haverinen; Rickard E Malmström; Mahan Nikpour-Ardaly; Magnus Röjvall; Martina Vallin; Eva Andersén-Karlsson; Marie-Louise Ovesjö
Journal:  BMC Health Serv Res       Date:  2018-03-12       Impact factor: 2.655

9.  Primary care physicians report high trust in and usefulness of the Stockholm drug and therapeutic committee's list of recommended essential medicines (the 'Wise List').

Authors:  Jaran Eriksen; Marie-Louise Ovesjö; Martina Vallin; Maria Juhasz-Haverinen; Eva Andersén-Karlsson; Kristina Ateva; Lars L Gustafsson; Malena Jirlow; Pia Bastholm-Rahmner
Journal:  Eur J Clin Pharmacol       Date:  2017-10-23       Impact factor: 2.953

10.  Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future.

Authors:  Winnie de Bruijn; Cristina Ibáñez; Pia Frisk; Hanne Bak Pedersen; Ali Alkan; Patricia Vella Bonanno; Ljiljana S Brkičić; Anna Bucsics; Guillaume Dedet; Jaran Eriksen; Joseph O Fadare; Jurij Fürst; Gisselle Gallego; Isabella P Godói; Augusto A Guerra Júnior; Hakkı Gürsöz; Saira Jan; Jan Jones; Roberta Joppi; Saim Kerman; Ott Laius; Newman Madzikwa; Einar Magnússon; Mojca Maticic; Vanda Markovic-Pekovic; Amos Massele; Olayinka Ogunleye; Aisling O'Leary; Jutta Piessnegger; Catherine Sermet; Steven Simoens; Celda Tiroyakgosi; Ilse Truter; Magnus Thyberg; Kristina Tomekova; Magdalena Wladysiuk; Sotiris Vandoros; Elif H Vural; Corinne Zara; Brian Godman
Journal:  Front Pharmacol       Date:  2016-07-22       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.